The Efficacy and Tolerability of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.

Trial Profile

The Efficacy and Tolerability of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Sumatriptan (Primary)
  • Indications Migraine; Nausea
  • Focus Registrational; Therapeutic Use
  • Acronyms PREDICT
  • Sponsors NuPathe
  • Most Recent Events

    • 01 Sep 2015 Results published in Teva Pharmaceuticals media release.
    • 14 Jul 2015 Results published in the Headache.
    • 08 Aug 2013 Post-hoc analyses presented at the 2013 International Headache Congress (IHC), according to a NuPathe media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top